论文部分内容阅读
[目的]探讨DcR3在卵巢上皮性良性及恶性肿瘤中的表达及其与卵巢癌临床病理特征的关系。[方法]采用免疫组织化学SP法检测106例卵巢上皮性肿瘤中DcR3和CA125的表达。[结果]DcR3在卵巢浆液性囊腺癌(71.0%)、卵巢子宫内膜样癌(44.4%)和卵巢透明细胞癌(83.3%)中出现过表达,并且与CA125的表达正相关(r=0.375,P=0.008)。在卵巢癌中,DcR3表达与患者年龄无相关性(P=0.067),与临床分期和组织分化水平具有相关性(P值分别为0.018、0.032)。[结论]DcR3在卵巢癌的发生发展中可能发挥着重要的作用,其在卵巢癌组织中的高表达,使其可能成为有效的治疗靶点。
[Objective] To investigate the expression of DcR3 in ovarian epithelial benign and malignant tumors and its relationship with clinicopathological features. [Method] Immunohistochemical SP method was used to detect the expression of DcR3 and CA125 in 106 cases of ovarian epithelial tumor. [Results] DcR3 was overexpressed in ovarian serous cystadenocarcinoma (71.0%), ovarian endometrioid carcinoma (44.4%) and ovarian clear cell carcinoma (83.3%), and positively correlated with the expression of CA125 (r = 0.375, P = 0.008). In ovarian cancer, DcR3 expression had no correlation with patient’s age (P = 0.067), and was correlated with clinical stage and tissue differentiation (P = 0.018, 0.032, respectively). [Conclusion] DcR3 may play an important role in the development of ovarian cancer. The high expression of DcR3 in ovarian cancer may make it an effective therapeutic target.